ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/KRAS-G12D-inhibitor-ON/OFF-state-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/KRAS-G12D-inhibitor-ON/OFF-state-inhibitor
7
trial(s) found.
NCT07659795
Advanced
Phase 2
Recruiting
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203) (
TARGET-D-203
)
KRAS G12D inhibitor,ON/OFF-state inhibitor
Colorectal adenocarcinoma
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT07659782
Advanced
Phase 2
Recruiting
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients With Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202) (
TARGET-D-202
)
KRAS G12D inhibitor,ON/OFF-state inhibitor
Non-small cell lung cancer
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT07644559
Advanced
Phase 2
Recruiting
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201) (
VS-7375-201
)
KRAS G12D inhibitor,ON/OFF-state inhibitor
anti-EGFR monoclonal antibody
Pancreatic adenocarcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT07522073
Advanced
Phase 3
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (
DAWN-303
)
KRAS G12D inhibitor,ON/OFF-state inhibitor
Pancreatic adenocarcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
2170 - Liverpool - Liverpool Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3121 - Richmond - Epworth Freemasons Hospital
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT07456046
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-003 Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation (
D3S-003-100
)
KRAS G12D inhibitor,ON/OFF-state inhibitor
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
NCT07020221
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors (
VS-7375-101
)
KRAS G12D inhibitor,ON/OFF-state inhibitor
Colorectal cancer
Non-small cell lung cancer
Pancreatic adenocarcinoma
Solid tumour
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
NCT06179160
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (
INCB161734-101
)
KRAS G12D inhibitor,ON/OFF-state inhibitor
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
WA
6009 - Nedlands - Linear Clinical Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (7)
Recruitment Country and State
QLD (4)
NSW (4)
VIC (4)
SA (3)
WA (2)
ACT (1)
Phase
Phase 1 (2)
Phase 1 / Phase 2 (1)
Phase 2 (3)
Phase 3 (1)
Trial Type
Advanced (7)
Cancer Therapy Class
KRAS
100%
EGFR
57%
PD-1
29%
PD-1/PD-L1
29%
TGFBR2
14%
Facility
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (3)
2109 - North Ryde - Macquarie University Hospital (3)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
3004 - Melbourne, Southbank - Alfred Health (2)
2170 - Liverpool - Liverpool Hospital (1)
2605 - Garran - The Canberra Hospital (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
6009 - Nedlands - Linear Clinical Research (1)
Cancer Type
Cancer
Solid tumour
Gastrointestinal cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Pancreatic cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Colorectal cancer
Lower gastrointestinal cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Colorectal adenocarcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy